Ranch Capital Advisors Inc. Acquires 1,323 Shares of Gilead Sciences, Inc. $GILD

Ranch Capital Advisors Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 22,365 shares of the biopharmaceutical company’s stock after purchasing an additional 1,323 shares during the quarter. Gilead Sciences comprises about 1.1% of Ranch Capital Advisors Inc.’s holdings, making the stock its 29th biggest holding. Ranch Capital Advisors Inc.’s holdings in Gilead Sciences were worth $2,480,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. Price T Rowe Associates Inc. MD raised its holdings in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new position in shares of Gilead Sciences in the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Gilead Sciences in the second quarter valued at about $238,083,000. Los Angeles Capital Management LLC increased its position in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. increased its position in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on GILD shares. Wolfe Research lifted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday. BMO Capital Markets lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $122.61.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $120.94 on Friday. The firm has a market capitalization of $150.06 billion, a P/E ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The business has a 50-day moving average of $115.47 and a 200-day moving average of $111.01. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the business posted $2.01 EPS. Gilead Sciences’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,500 shares of company stock worth $8,281,540 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.